Differential expression of sprouty genes in hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 105, Issue 3, 2012, Pages 273-276

  Sirivatanauksorn, Yongyut ^a   Sirivatanauksorn, Vorapan ^b   Srisawat, Chatchawan ^b   Khongmanee, Amnart ^b   Tongkham, Chalita ^b  

^a Division of General Surgery   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

angiolymphatic invasion; cirrhosis; hepatocellular carcinoma; Sprouty; SPRY

Indexed keywords

MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPROUTY 1 GENE; SPROUTY 2 GENE; SPROUTY 3 GENE; SPROUTY 4 GENE; UPREGULATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PHOSPHOPROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84856294824     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22095     Document Type: Article

References (24)

1. Ferlay J, Shin H, Bray F, et al.: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. In: Lyon, France: International Agency for Research on Cancer; 2008.
2. Farazi PA, DePinho RA,: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-687. (Pubitemid 44286000)
3. Hacohen N, Kramer S, Sutherland D, et al.: Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998; 92: 253-263. (Pubitemid 28073048)
4. Kim HJ, Bar-Sagi D,: Modulation of signalling by Sprouty: A developing story. Nat Rev Mol Cell Biol 2004; 5: 441-450. (Pubitemid 38745494)
5. Lo TL, Fong CW, Yusoff P, et al.: Sprouty and cancer: The first terms report. Cancer Lett 2006; 242: 141-150. (Pubitemid 44515046)
6. Lo TL, Yusoff P, Fong CW, et al.: The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004; 64: 6127-6136. (Pubitemid 39129413)
7. Kwabi-Addo B, Wang J, Erdem H, et al.: The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004; 64: 4728-4735. (Pubitemid 38924514)
8. McKie AB, Douglas DA, Olijslagers S, et al.: Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005; 24: 2166-2174. (Pubitemid 40516583)
9. Tsavachidou D, Coleman ML, Athanasiadis G, et al.: SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004; 64: 5556-5559. (Pubitemid 39095548)
10. Fong CW, Chua MS, McKie AB, et al.: Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006; 66: 2048-2058.
11. Livak KJ, Schmittgen TD,: Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
12. American Liver Tumor Study Group: A randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. In: Investigators booklet and protocol. Richmond, VA: United Network for Organ Sharing; 1998.
13. Lee SA, Ho C, Roy R, et al.: Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 2008; 47: 1200-1210. (Pubitemid 351547906)
14. Feng YH, Wu CL, Tsao CJ, et al.: Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. Cancer Biol Ther 2011; 11: 111-121.
15. Kosuge T, Makuuchi M, Takayama T, et al.: Long-term results after resection of hepatocellular carcinoma: Experience of 480 cases. Hepatogastroenterology 1993; 40: 328-332. (Pubitemid 23258549)
16. Lee CC, Putnam AJ, Miranti CK, et al.: Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 2004; 23: 5193-5202. (Pubitemid 38980352)
17. Mu Z, Wang H, Zhang J, et al.: KAI1/CD82 suppresses hepatocyte growth factor-induced migration of hepatoma cells via upregulation of Sprouty2. Sci China C Life Sci 2008; 51: 648-654. (Pubitemid 351999748)
18. Taniguchi K, Ishizaki T, Ayada T, et al.: Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth. Cancer Sci 2009; 100: 1648-1654.
19. Wang J, Thompson B, Ren C, et al.: Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 2006; 66: 613-624.
20. Egan JE, Hall AB, Yatsula BA, et al.: The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA 2002; 99: 6041-6046. (Pubitemid 34493261)
21. Yang X, Harkins LK, Zubanova O, et al.: Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia. Dev Biol 2008; 321: 64-76.
22. Schaaf G, Hamdi M, Zwijnenburg D, et al.: Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene. Cancer Res 2010; 70: 762-771.
23. Cabrita MA, Christofori G,: Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008; 11: 53-62.
24. Anteby EY, Natanson-Yaron S, Greenfield C, et al.: Human placental Hofbauer cells express sprouty proteins: A possible modulating mechanism of villous branching. Placenta 2005; 26: 476-483. (Pubitemid 40796575)